← Back to list

L&G Pharma Breakthrough UCITS ETF

Solactive Pharma Breakthrough Value

Equities
ISIN
IE00BF0H7608
Issuer
Legal & General (LGIM)
TER
0.49%
Latest closing price
N/A
Fund Size
€20 m As of: Sep 30, 2026
Domicile
Ireland
Distribution Policy
Accumulating
Replication Method
Physical
Base Currency
USD
WKN / Ticker
A2H9XR / ETLI

Data availability

Data is available for 2 of 5 areas for this fund.

  • Master data (TER, index, size): As of: Sep 30, 2026
  • Closing price: not available
  • Price history (at least 20 prices): not available
  • Holdings: As of: Jul 28, 2026
  • Risk figures: not available

Missing information is marked as “not available” and is not estimated. The issuer’s documents are authoritative.

At a glance

L&G Pharma Breakthrough UCITS ETF (ISIN IE00BF0H7608) is a fund from Legal & General (LGIM) (fund type: ETF). Benchmark index: Solactive Pharma Breakthrough Value. Its ongoing charges (TER) are 0.49% per year. The fund size is €20 m. Distribution policy: Accumulating. Replication: Physical. Fund domicile: Ireland.

Key Facts
  • Launch date 23.01.2018 (8 years)
  • Number of Holdings 36
  • Strategy Passive (index tracking)
  • Base Currency USD
  • Currency hedging No
  • Distribution Policy Accumulating
  • Replication Method Physical
  • Securities lending Yes
  • Domicile IE
  • UCITS Compliant Yes

Price development

Error loading comparison.
There is not enough price data available for this period yet.

Pure price change based on stored closing prices; distributions, purchase costs and taxes are not included. Different currencies and index types (price or total return index) can distort the comparison line. Past performance is not a reliable indicator of future results.

Risk figures (12 months)

No calculated risk figures are available for this fund yet.

The official summary risk indicator (SRI, scale 1–7) is in the issuer’s key information document (KID). The figures here are historical values and do not replace it.

Documents

We have no documents stored for this fund. The key information document (KID), factsheet and prospectus are provided by the issuer.

Tracking difference and tracking error

We have no comparison series stored for this fund’s index, so a tracking analysis is not possible.

What does the fund invest in?
As of 28.07.2026 · Source: justETF / etfdb
Sector Breakdown
  • Health care 97.1%
  • Industrials 1.8%
  • Other 1.1%
Country Breakdown
  • United States 62.5%
  • Japan 8.4%
  • Switzerland 4.9%
  • Netherlands 4.9%
  • Ireland 3.4%
  • China 2.9%
  • Sweden 2.8%
  • Denmark 2.6%
  • France 2.4%
  • Spain 2.3%
  • All others 2.9%

Holdings

Showing 10 holdings that together make up 35.5 % of fund assets. (out of 36 holdings in total).

# Name ISIN Sector Country Weight
1 Travere Therapeutics US89422G1076 – – 4.95 %
2 Xencor, Inc. US98401F1057 – – 4.25 %
3 Ligand Pharmaceuticals, Inc. US53220K5048 – – 3.54 %
4 Xeris Biopharma Holdings US98422E1038 – – 3.42 %
5 Jazz Pharmaceuticals IE00B4Q5ZN47 – – 3.40 %
6 Incyte Corp. US45337C1027 – – 3.27 %
7 Royalty Pharma GB00BMVP7Y09 – – 3.18 %
8 Agios Pharmaceuticals US00847X1046 – – 3.16 %
9 BridgeBio Pharma, Inc. US10806X1028 – – 3.16 %
10 Mirum Pharmaceuticals US6047491013 – – 3.14 %
Cost calculator
What does this ETF cost you per year – and over your whole investment horizon?
Cost in year 1
–
Total cost impact
–

Simplified model based on the TER, excluding order fees, spreads, taxes and tracking difference. Not investment advice.

Alternatives on the same index
Other ETFs tracking the Solactive Pharma Breakthrough Value – cheapest first.
We know of no other ETFs tracking exactly this index.

Frequently asked questions about the L&G Pharma Breakthrough UCITS ETF

The total expense ratio (TER) of the L&G Pharma Breakthrough UCITS ETF is 0.49% per year. The costs are deducted from the fund assets on an ongoing basis and are already reflected in its performance.

The L&G Pharma Breakthrough UCITS ETF tracks the Solactive Pharma Breakthrough Value. Our index encyclopedia explains the index and lists all funds that track it.

The L&G Pharma Breakthrough UCITS ETF is accumulating: income such as dividends is not paid out but automatically reinvested in the fund.

The L&G Pharma Breakthrough UCITS ETF uses physical replication: it holds the securities of the index directly – either in full or as a representative sample (sampling).

The fund size of the L&G Pharma Breakthrough UCITS ETF is €20 m. A large fund size usually indicates good tradability and a lower risk of the fund being closed.

The L&G Pharma Breakthrough UCITS ETF is domiciled in Ireland. The fund domicile affects, among other things, how withholding taxes are treated inside the fund.

The provider (issuer) of the L&G Pharma Breakthrough UCITS ETF is Legal & General (LGIM).

All information without guarantee. It is provided for information purposes only and does not constitute investment advice.